abc biopply announces today the opening of its new Organoid Competence Center at the Swiss Innovation Park Basel. With this new location, the company expands its portfolio of highly standardized and fully integrated Organoid CRO services and brings them for the first time to Basel — one of the world’s leading hubs for drug discovery and development.

PSI CRO, a Swiss-based global full-service contract research organization (CRO), today announced the launch of SYNETIC, a next-generation AI-powered semantic knowledge platform that empowers sponsors to identify optimal trial sites, minimize startup delays, and predict and eliminate non-enrolling sites.

abc biopply ag and Pathways Preclinical Partners (“Path2P”) today announced a new collaboration aimed at enforcing the integration of abc biopply’s cutting-edge preclinical NAM technology 3D CoSeedis within global drug development networks in the US.

PSI CRO, a global, Swiss-based CRO, closed 2025 as its strongest year to date, marking its 30th anniversary with solid operational and financial performance. The only fully independent and privately owned global CRO, the company achieved 15% revenue growth, a 52% new customer growth, and a 93% repeat business rate while continuing global expansion fueled by its unique delivery model.